Digital Health Innovation and Informatics

PV QA 2 - Poster Viewing Q&A 2

MO_19_2863 - The METABANK Score: A Clinical Tool to Predict Survival after Stereotactic Radiation Therapy for Oligometastatic Disease

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

The METABANK Score: A Clinical Tool to Predict Survival after Stereotactic Radiation Therapy for Oligometastatic Disease
R. Van den Begin, B. Engels, C. Collen, and M. De Ridder; Radiotherapy Department, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Purpose/Objective(s): Stereotactic radiotherapy (SRT, SBRT) is nowadays widely used in oligometastatic cancer. The oligometastatic state is however vaguely demarcated and the heterogeneity of the population complicates estimation of the prognosis. We aimed to investigate the role of different clinical parameters, the modified Glasgow Prognostic Scale, the Neutrophil-Lymphocyte Ratio, and the influence of metformin and aspirin use.

Materials/Methods: Patients were included if treated in our center with SRT for 1-5 oligometastases between 2003 and 2017. Patients were randomized between a model training set (2/3) and a separate validation set (1/3). A Cox regression model was built, validated and risk points were attributed to the resulting parameters.

Results: 403 patients received SRT for 760 metastases and median follow-up reached 42 months. Treated sites were mainly lung, liver, nodal areas, and brain. Most common primaries were colorectal and lung cancer. Median OS (MS) was 26.6 months for the complete cohort (95% CI 23.8-29.3). Five independent adverse factors were discriminated: Male sex, synchronous Timing of oligometastatic occurrence, Brain metastasis, Non-adenocarcinoma histology, KPS<80. A risk score is formed by summation of the points of each factor (M:4, T:2, B:7, N:7, K:8). Four risk groups were defined: (1) 0-2 points: MS 41.2 months (95% CI 30.2-52.3); (2) 3-8 points: 29.3 months (24.6-34.0); (3) 9-13 points: 17.4 months (10.1-24.7), and (4) 14-28 points: 7.9 months (5.5-10.3).

Conclusion: We propose a prognostic score that can be used in a variety of primary tumors and disease locations, including presence or absence of brain metastases. The nomogram and risk groups can be used to stratify patients in new trials and support a multidisciplinary tumor board to offer individualized care for oligometastatic patients.

Author Disclosure: R. Van den Begin: None. B. Engels: None. M. De Ridder: Research Grant; Kom op Tegen Kanker, Antikankerfonds, Stichting tegen Kanker. Data management support; Accuray.

Send Email for Robbe Van den Begin


Assets

MO_19_2863 - The METABANK Score: A Clinical Tool to Predict Survival after Stereotactic Radiation Therapy for Oligometastatic Disease



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for The METABANK Score: A Clinical Tool to Predict Survival after Stereotactic Radiation Therapy for Oligometastatic Disease